Endometriosis
Pipeline by Development Stage
Drug Modality Breakdown
Women's Health is a $989M market with mature, consolidated portfolios dominated by legacy hormone therapies and specialty oncology agents.
Key Trends
- Heavy concentration in estrogen receptor agonists and single-blockbuster dependency (INLYTA 47% of market)
- Multiple patent cliffs 2027-2030 creating near-term revenue pressure and consolidation risk
- Hiring concentrated in commercial and specialty recruitment, not R&D expansion
Career Verdict
Viable but cautious entry point—stable commercial roles available, but limited innovation pipeline and impending LOE events suggest a mature market in defensive posture rather than growth mode.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | INLYTA (axitinib) | Pfizer | $0.467B | 47% | Peak | Stable | 11.2yr |
| 2 | KORLYM (mifepristone) | Corcept Therapeutics | $0.229B | 23% | Peak | Stable | 12.2yr |
| 3 | LUPRON DEPOT (leuprolide acetate) | AbbVie | $0.129B | 13% | LOE Approaching | Declining | |
| 4 | ESTRING (estradiol) | Pfizer | $0.050B | 5% | LOE Approaching | Declining | |
| 5 | PREMPRO (conjugated estrogens/medroxyprogesterone) | Pfizer | $0.040B | 4% | LOE Approaching | Declining |
Drug Class Breakdown
single-product dominance (INLYTA)
concentrated in specialty reproductive health
legacy product with pending LOE pressure
fragmented across 17 products, majority LOE-approaching
minor indication-specific use
niche positioning, small market share
Career Outlook
StableWomen's Health is a mature, consolidated market where career growth is incremental rather than exponential. Pfizer and AbbVie control ~61% of spending via blockbuster and legacy products, creating stable but competitive commercial environments. Impending patent cliffs (2027-2030) and fragmented early-stage pipeline suggest cost containment and defensive strategy dominance over expansion, meaning fewer senior advancement slots and limited innovation-driven upside. Opportunity exists in specialty segments (fertility platforms, digital health, device innovation) outside traditional pharma.
Breaking In
Target specialty commercial roles (MSL, outcomes research) or non-traditional employers (Progyny, digital health startups, device firms) rather than incumbent pharma, which offers less differentiation for new entrants.
For Experienced Professionals
Experienced professionals should assess portfolio defensibility and patent cliff timing before joining a company; AbbVie and Pfizer offer scale but entail consolidation risk, while boutique firms (Corcept, Duchesnay) offer strategic leverage in niche areas.
In-Demand Skills
Best For
Hiring Landscape
Women's Health hiring totals 117 jobs, but data shows significant reporting gaps (many major companies report 0 jobs despite large portfolios). Visible hiring is concentrated in Viatris (40 jobs, likely manufacturing/supply chain post-spinoff), Progyny (29 jobs, fertility/reproductive benefits platform), and specialized device/diagnostics firms (GE HealthCare, Caldera Medical, Natera). Commercial roles dominate disclosed positions (65 of 109 departmental roles), with IT second (7 roles at $222K avg, reflecting digital health emphasis).
Top Hiring Companies
By Department
Commercial and specialty sales roles offer stable near-term opportunity, but modest average salary ($82K commercial) and portfolio maturity suggest limited high-growth compensation upside; IT roles offer premium but are scarce.
On Market (2)
Approved therapies currently available
Competitive Landscape
38 companies ranked by most advanced pipeline stage
+8 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 47 trials with date data
Clinical Trials (50)
Total enrollment: 11,534 patients across 50 trials
Comparison Between the Effects of Implantable Gestrinone and Oral Dienogest in the Treatment of Endometriosis
Decapeptyl SR With Livial Add Back Therapy in the Management of Chronic Cyclical Pelvic Pain in Pre Menopausal Women
Endometrial Markers and Response of Endometriosis Patients to Prolonged GnRH Agonist Prior to IVF
Evaluate the Efficacy and Safety of HMI-115 in Women With Moderate to Severe Endometriosis-associated Pain
Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain
Clinical Study to Compare Efficacy and Safety of Indinol Forto® 200 mg Capsules and Visanne 2 mg Tablets in Treatment of Endometriosis
A Clinical Study of KLH-2109 in Patients With Endometriosis
Effect GnRH Agonist Administration in Endometriosis Cyst Patients
Efficacy and Safety of BG2109 in Chinese Subjects With Endometriosis
A Study to Evaluate Safety and Efficacy of Elagolix in Patients With Moderate to Severe Endometriosis-Associated Pain
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain
Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain
Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6)
Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.
A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain
Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With Endometriosis
A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe Pain
Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain
Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women With Moderate to Severe Endometriosis-associated Pain
Phase 3 Study of Dienogest for the Treatment of Endometriosis in Chinese Patients
Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Adults With Moderate to Severe Endometriosis-Associated Pain
Comparative Study of BAY86-5300 With an Extended Flexible Regimen for Endometriosis
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain
Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg)
Safety and Efficacy of SH T00660AA in Treatment of Endometriosis
Medical Treatment of Endometriosis-Associated Pelvic Pain
Efficacy and Safety of SH T00660AA in Treatment of Endometriosis
Mifepristone 2.5, 5, 10 mg Versus Placebo in the Treatment of Endometriosis
Effect of Rosiglitazone on Peritoneal Cytokines in Women With Endometriosis
A Randomized Open Label Study of KLH-2109 in Patients With Endometriosis(1)
A Randomized, Placebo-controlled, Double-blind Study of KLH-2109 in Patients With Endometriosis (2)
A Phase II Randomized Open Label Study of KLH-2109 in Patients With Endometriosis
A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis
Efficacy of SN132D in Patients With Suspected Endometriosis
A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain
Study to Evaluate the Pharmacodynamics and Efficacy of Leuprolide Tablets (Ovarest®) in Women With Endometriosis
A Study to Assess the Efficacy and Safety of HMI-115 in Subjects With Endometriosis-Associated Pain
Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside of the Womb
Cabergoline for the Treatment of Chronic Pain Due to Endometriosis
Quinagolide Vaginal Ring on Lesion Reduction Assessed by MRI in Women With Endometriosis/Adenomyosis
Assess Safety and Efficacy of Vilaprisan in Subjects With Endometriosis
Study to Determine Intraperitoneal,Tissue, Serum Concentrations of VML-0501 Following Five Days of Daily Vaginal Single Dose of VML-0501 (100 mg Danazol), in Comparison to Oral Danazol Capsules Daily 600 mg), in Women With Signs and Symptoms of Endometriosis Undergoing Laparoscopy
A Study to Test Whether Study Drug BAY1128688 Brings Pain Relief to Women With Endometriosis and if so to Get a First Idea Which Dose(s) Work Best
A Study of Pharmacokinetic/Pharmacodynamic Profile of Orally Administered Leuprolide in Healthy Female Volunteers
Late Phase II Clinical Study of KLH-2109 in Patients With Endometriosis
Traditional Chinese Medicine Sequential Treatment for Endometriosis Associated Infertility
A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic Pain
Visanne Study to Assess Safety in Adolescents
BGS649 Monotherapy in Moderate to Severe Endometriosis Patients
Related Jobs in Women's Health
Urology Gynecology Sales Representative - Future Opportunity
Territory Representative - Birmingham
Medical Science Liaison, Women's Health
Medical Director, Women’s Health - MFM
General Medicines, Commercial Director, Menopause
Scientist, Reproductive & Molecular Biology
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.